One of DTA's top priorities for 2023,  this bill will enable public coverage of prescription digital therapeutics, defined in this bill as a product that uses software to achieve its intended result, is cleared or approved by the Food and Drug Administration (FDA) for the prevention, management, or treatment of a medical condition, and is authorized by a qualified, licensed clinician.

If passed, the Access to Prescription Digital Therapeutics Act will establish a payment methodology for manufacturers of prescription digital therapeutics, product-specific Healthcare Common Procedure Coding System (HCPCS) codes, and a DTx manufacturer reporting process to the Centers for Medicare and Medicaid Services (CMS).

This legislation comes at a critical moment for patients and marks an important step toward expanded patient access to DTx therapies for a wide range of conditions. DTA supports the Access to Prescription Digital Therapeutics Act of 2023 and urges Congress to pass it. 

DTA set up this easy to navigate process for anyone who is willing to communicate directly with their Members of Congress, asking them to co-sponsor and enact this important piece of legislation. A standardized core message is already pre-populated in the form. You are also invited to include a brief introductory statement describing your interest in digital therapeutics, your work in the DTx industry, the impact DTx products have on patient care, and why this bill is important to you. To send this message, please enter your contact information and your zip code (which will determine which congressional representatives receive your message). 

Thank you for your advocacy. Feel free to contact Sara Elalamy at Sara@dtxalliance.org if you have any questions.